Loading
A phase 2 trial of Pemetrexed, Cisplatin, IBI363 in non-small-cell lung cancer and small-cell lung cancer, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07122687 by Innovent Biologics (Suzhou) Co. Ltd., with 170 participants planned, started 2025-08-26 and due to reach its primary completion in 2026-11-30. Interventions recorded: Pemetrexed, Cisplatin, IBI363, Carboplatin, Keytruda. Conditions listed: Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Innovent Biologics, Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Cisplatin.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Carboplatin, Small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Cisplatin, Carboplatin.
Shares IBI363, Innovent Biologics, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/